Pregnancy: There is no sufficient data to determine the safety of Serratiopeptidase for humans during pregnancy. There are insufficient animal studies regarding the effects of Serratiopeptidase on pregnancy, embryonal/fetal development, birth and postnatal development. Serratiopeptidase may be prescribed during pregnancy only if clearly indicated.
Lactation: It is not known that Serrapeptase, the active ingredient of Kuserta is excreted in human milk. No adverse effects were observed during lactation in children of mothers undergoing treatment with serrapeptase.